BioSpace News Archive

IMV Inc. (Nasdaq: IMV; TSX: IMV), the clinical stage immuno-oncology corporation, today announced that the 2019 International Conference on Malignant Lymphoma (ICML) will publish an abstract on the company’s combination immunotherapy trial titled, “Phase 2 Study: DPX-Survivac with Intermittent Low Dose Cyclophosphamide and Pembrolizumab in Patients with recurrent/refractory Diffuse Large B-Cell Lymphoma – The SPiReL trial.”

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced the schedule of presentations on BIJUVATM (estradiol and progesterone capsules, 1 mg/100 mg) and ANNOVERA™ (segesterone acetate/ethinyl estradiol vaginal system) at the American College of Obstetricians and Gynecologists (ACOG) 2019 Annual Meeting in Nashville on May 3-6, 2019

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced that results from the pivotal rimegepant Zydis® ODT Phase 3 clinical trial will be presented as a late-breaking oral presentation at the 2019 American Academy of Neurology (AAN) Annual Meeting in Philadelphia, May 4-10, 2019.

Results from one of the largest datasets in uterine cancer presented at The American College of Obstetricians and Gynecologists (ACOG) Annual Clinical and Scientific Meeting

Meaningful advantages of MOSES for BPH procedures and the continuous flow of clinical evidence for its use in lithotripsy

The World’s Largest Cleft Charity Hosts Star-Studded 20th Anniversary Gala, with Alexa Ray Joel, Kelly Rutherford, Dikembe Mutombo, Rev Run, Kenyan Drake, Kristen Taekman and many others

Caris Life Sciences®, a leading innovator in molecular science focused on precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for the company’s MI Transcriptome™ companion diagnostic (CDx) test.

Hi-Tech Pharmaceuticals sued the FDA May 2nd, 2019 in Federal Court- Case 1:19-cv-01268, claiming the agency bypassed standard rule-making procedures in favor of a campaign of intimidation to try to force companies to destroy their products containing 2-Aminoisopheptane, or DMHA

The Green Organic Dutchman Holdings Ltd. (the “Company” or “TGOD”) (TSX:TGOD) (US:TGODF) is pleased to confirm that the Hamilton City Council and the Company have finalized and signed a settlement offer, and that the Local Planning Appeal Tribunal approved the settlement at a meeting on May 2, 2019.

Allergan plc, (NYSE: AGN), a leading global pharmaceutical company with a heritage of more than 70 years in eye care, will present new data for its investigational implant, Bimatoprost SR, and a late-breaking analysis on its subconjunctival gelatin implant, XEN Gel Stent, at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting to be held in San Diego, California from May 3rd – 7t